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Introduction: Esophageal carcinoma is characterized by a high fre-
quency of lymph node metastasis (LNM). It is difficult to accurately 
define the radiotherapeutic clinical target volume in patients with tho-
racic esophageal squamous cell carcinoma (ESCC), because the LNM 
rate and the included node level varied greatly among previous studies. 
This study aimed to determine which node level should be included for 
radiotherapy by analyzing LNM rate in thoracic ESCC patients.
Methods: The clinicopathological factors related to LNM were ana-
lyzed using the χ2 test. The sites with LNM rate higher than 15%, 
an empirical cutoff value, were considered as high-risk areas and 
were included in clinical target volume of thoracic ESCC patients 
for radiotherapy.
Results: This study included 1893 thoracic ESCC patients treated 
at Shandong Cancer Hospital, Jinan, China. The rates of LNM in 
patients with upper thoracic tumors were 14.6% cervical, 29.3% 
upper mediastinal, 8.5% middle mediastinal, 9.8% lower mediasti-
nal, and 7.3% abdominal, respectively. The rates of LNM in patients 
with middle thoracic tumors were 4.3%, 5.0%, 32.9%, 2.5%, and 
14.9%, respectively. The rates of LNM in patients with lower tho-
racic tumors were 2%, 2.2% 15.4%, 38.1%, and 27.5%, respectively. 
Independent prognostic factors for LNM included length of tumor, 
histologic differentiation, and depth of tumor invasion (p < 0.001).
Conclusions: Irradiation of the selective regional lymph node and 
the correlated lymphatic drainage regions should be performed 
according to the clinicopathological factors. For the large, deeply 
invasive longer tumors and poorly differentiated thoracic ESCC, the 
irradiation field should be enlarged appropriately.
Key Words: Esophageal neoplasms, Radiotherapy, Clinical target 
volume.
(J Thorac Oncol. 2013;8: 359-365)
Esophageal carcinoma is characterized by a high frequency of lymph node metastasis (LNM), and surgery is the main-
stay of treatment for operable esophageal carcinoma.1 The pat-
tern of LNM is one of the definitive factors influencing both 
the overall survival rate, and therapeutic decision making of 
esophageal carcinoma. Tachikawa et al.2 reported that the met-
astatic mode of lymph node can reflect the degree of esopha-
geal cancer progression and thus was an important prognostic 
factor. Ooki et al.3 showed that LNM density and growth were 
the most important prognostic factors in esophageal squa-
mous cell carcinoma (ESCC). Therefore, the understanding of 
risk factors related to LNM is beneficial in identifying patients 
who are more likely to have lymph nodes involved and in guid-
ing the individualized therapy. However, systemic and local 
recurrence remains high in advanced esophageal carcinoma 
even after complete tumor resection and extensive lymphad-
enectomy, resulting in low 5-year survival rate.4 In addition, 
most of the esophageal carcinomas are already in an advanced 
stage when diagnosed, thus surgery is inappropriate in up to 
40% to 60% of patients because of reasons such as unresect-
able tumor, presence of distant metastases, and high operative 
risk.5 These patients are usually treated with radiotherapy.
There is consensus that the gross tumor volume con-
sists of the primary tumor and positive lymph nodes. However, 
there is no general recommendation on the lymph node regions 
that should be included in the clinical target volume (CTV) 
for radiotherapy. In this study, the pattern of LNM in ESCC 
patients treated with three-field or two-field lymphadenectomy 
was analyzed, and the impact of LNM on the radiotherapeutic 
CTV delineation in thoracic ESCC was investigated.
PATIENTS AND METHODS
Patients Characteristics
All patients underwent computed tomography or 
positron emission tomography scans for preoperative staging 
workup. Cervical ultrasonography was also performed for the 
detection of cervical lymphadenopathy. The exclusion criteria 
included preoperative radiotherapy or chemotherapy, invasion 
to cervical esophagus and cardiac part of the stomach, and 
distant metastasis. Informed consent was obtained from each 
patient. This study was approved by the Ethics Committee of 
our hospital. The demographic information of the patients is 
shown in Table 1.
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Surgical Procedures
All patients received transthoracic esophagectomy 
with extensive lymphadenectomy, using either two-field or 
three-field approach. Patients without cervical lymph node 
swelling received two-field lymph node dissection. Two-field 
lymphadenectomy included total mediastinal, perigastric, and 
celiac lymph node. Patients with cervical lymph node swelling 
received three-field lymph node dissection. Three-field lymph-
adenectomy was performed through a right thoracotomy, lapa-
rotomy, and bilateral cervical collar. The azygous vein and the 
right bronchial artery were ligated, but in some selected cases, 
the right bronchial artery could be preserved to prevent tra-
cheal ischemia and necrosis. The superior vena cava, innomi-
nate artery, right subclavian artery, pulmonary branch of the 
right vagal nerve, and the bilateral recurrent laryngeal nerves 
were carefully exposed and preserved.
Naming and Numbers of Lymph Node Stations
To accurately describe the incidence and pattern of 
LNM and the extent of lymphadenectomy, the terminology of 
the regional lymph nodes of esophageal cancer was defined 
by the Japanese Society for Esophageal Diseases (Table 2).6,7
Clinicopathological Examination
To identify the risk factors associated with LNM of 
ESCC, several clinicopathological parameters were assessed, 
including the patient’s sex, age, location of the tumor, patho-
logical type, T stage, length of tumor, and histologic differ-
entiation of the tumor. All resected specimens and resected 
lymph nodes were fixed in 10% formalin and paraffin. These 
paraffin specimens were sectioned and stained by hematoxy-
lin and eosin. All histopathologic examinations were per-
formed independently and blindly by two pathologists, and 
TABLE 1.  Clinicopathological Features of 1893 Patients with Thoracic Esophageal Squamous Cell Carcinoma and Univariate 
Analysis of Clinicopathological Factors Associated with Lymph Node Metastasis
Characteristics Total Number Number of LNM χ2 p
Sex 0.379 0.538
 Men 1474 668
 Women 419 197
Age (yr) 6.190 0.045
 ≤ 40 19 9
 41–59 906 445
 ≥ 60 968 420
Locations 2.139 0.343
 Upper esophagus 82 42
 Middle esophagus 1266 564
 Lower esophagus 545 257
Pathological morphology 10.025 0.038
 Ulcer 1040 481
 Marrow 738 342
 Massive 75 22
 Narrow 32 16
 Intracavity 8 2
Length of tumor (cm) 45.759 <0.001
 ≤ 2.0 230 89
 2.1–4.0 830 330
 4.1–6.0 614 324
 6.1–8.0 170 96
 > 8.0 49 33
Depth of tumor invasion 18.190 0.001
 Tis 10 7
 T1 103 33
 T2 345 156
 T3 1173 525
 T4 262 142
Tumor differentiation 16.526 <0.001
 Well 429 172
 Moderate 1185 534
 Poor 279 155
LNM, lymph node metastasis.
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all histopathologic factors used in this study were abstracted 
from the medical records.
Statistical Analysis
The relationship between the clinicopathological factors 
and the LNM was evaluated using the χ2 test. For multivari-
ate analysis, the forward step-wise procedure was performed 
using a binary logistic regression model, containing all statis-
tically significant variables in univariate analysis. p Value of 
less than 0.05 was considered statistically significant. SPSS 
18.0 software package was used (SPSS, Chicago, IL).
The sites with LNM rate higher than 15%, an empiri-
cal cutoff value, were considered as high-risk areas and were 
included in CTV of thoracic ESCC patients for radiotherapy.
RESULTS
From February 2003 to September 2011, 1893 patients 
with thoracic ESCC were surgically treated at Shandong 
Cancer Hospital.
Tumor Locations and LNM
The LNM sites of thoracic esophageal carcinomas are 
shown in Table 3 and Figure 1. Table 4 shows the LNM sites 
of thoracic ESCC. A total of 25,410 nodes were removed from 
1893 patients, with a mean of 13.4 nodes per patient. Lymph 
node metastases were found in 865 of the 1893 patients, the 
rate of LNM was 45.7% (865 of 1893).
Clinicopathological Factors Associated 
with LNM and Subgroup Analysis
The length of tumor (p < 0.001), histologic differentia-
tion (p < 0.001), depth of tumor invasion (p = 0.001), patho-
logical type (p = 0.038), and age (p = 0.045) were closely 
associated with LNM shown by univariate analysis (Table 1). 
Multivariate analysis suggested that age (p = 0.020, odds 
ratio [OR] = 0.988), depth of tumor invasion (p < 0.001, 
OR = 1.735), length of tumor (p < 0.001, OR = 1.155), 
and histologic differentiation (p < 0.001, OR = 1.980) were 
strongly associated with LNM (Table 5). The results of further 
subgroup analysis about tumor invasion, length of tumor, and 
histologic differentiation are shown in Table 6.
DISCUSSION
The present study indicates that the pattern of LNM in 
ESCC is associated with the tumor location, depth of tumor 
invasion, length of tumor, histologic differentiation, and age. 
These factors should be considered comprehensively when 
designing the CTV for radiotherapy of ESCC.
In the present study, 1893 patients with thoracic ESCC 
were treated with esophagectomy and lymphadenectomy. The 
role of three-field lymph node dissection in esophageal cancer 
surgery is controversial.8 Tachibana et al.9 showed that the sur-
vival rate was significantly improved in ESCC patients treated 
with three-field lymph node dissection compared with two-
field lymph node dissection. In contrast, Shim et al.10 found 
that there was no survival benefit from the addition of cervi-
cal nodal dissection in esophagectomy for ESCC. We suggest 
that cervical nodal dissection can be omitted in selected cases, 
especially for patients who have no cervical LNM on preop-
erative staging workup.
It has been shown that the depth of tumor invasion,11 
length of tumor,12 and histologic differentiation13 were asso-
ciated with the LNM in ESCC. Similarly, our results also 
suggest the independent prognostic factors for LNM include 
depth of tumor invasion (p < 0.001, OR = 1.753), length of 
tumor (p < 0.001, OR = 1.155), and histologic differentiation 
(p < 0.001, OR = 1.980) (Table 5). We found that age was a 
significant predictor of LNM (p = 0.020, OR = 0.988), which 
was inconsistent with our previous study.14 The age range of 
patients in this study was 30 to 85 years, and they were arbi-
trarily divided into three age groups, 40 years and lesser, 41 to 
59 years, and 60 years or more. It is interesting to note that the 
percentage of positive node was higher in the younger groups 
(≤40 years, 47.3% positive; 41–59 years, 49.1% positive) than 
in the older group (≥60 years, 43.3% positive) (p < 0.05). 
Old age is generally regarded a negative prognostic factor for 
LNM in thoracic ESCC, yet our results show that the younger 
age group was associated with an increased risk of LNM. 
However, this finding does not mean that older patients have 
lower risks of LNM in ESCC than younger ones. Our results 
highlight the important role of age in LNM in thoracic ESCC. 
TABLE 2.  Terminology of the Regional Lymph Nodes in 
Esophageal Cancer
JSED Numbering
Superficial cervical (R, L) 100
Cervical paraesophageal (R, L) 101
Deep cervical (R, L) 102
Peripharyngeal (R, L) 103
Supraclavicular 104
Upper thoracic paraesophageal 105
Middle thoracic paraesophageal 108
Lower thoracic paraesophageal 110
Recurrent nerve (R) 106 rec
Recurrent nerve (L) 106 rec
Pretracheal 106 pre
Tracheobronchial (L) 106 tbL
Bifurcational 107
Main bronchus (R, L) 109
Supradiaphragmatic 111
Posterior mediastinal 112
Ligamentum arteriosum (Botallo’s node) 113
Anterior mediastinal 114
Cardiac (R, L) 1, 2
Lesser curvature 3
Greater curvature 4
Left gastric artery 7
Common hepatic artery 8
Splenic artery 11
Coeliac artery 9
JSED, Japanese Society for Esophageal Diseases; R, right; L, left.
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These unfavorable risk factors should be taken into account 
when the probability of LNM is evaluated for the treatment 
design of ESCC.
The prevalence of lymphatic metastasis varies in esoph-
ageal carcinoma of different locations. We speculate that 
LNM in the upper thoracic esophageal carcinoma tends to 
appear upward, whereas LNM in the lower thoracic esopha-
geal carcinoma tends to appear downward. In the middle tho-
racic esophageal carcinoma, LNM could appear both upward 
and downward, with the latter accounting for a higher propor-
tion. In contrast, in the lower thoracic esophageal carcinoma, 
the most common LNM site was the abdominal nodes.
Radiation therapy is an important treatment modality 
for the local control of esophageal carcinoma.15,16 Although 
concurrent chemotherapy and radiotherapy have been used as 
the standard treatments for advanced esophageal carcinoma, 
locoregional control rates are still below 50% and the 5-year 
overall survival rate is only 26%.17 Esophageal cancer is 
characterized by the high rate of nodal involvement and 
its spread pattern is not always predictable. In addition, 
skip metastases are frequently observed in esophageal 
cancer.18–20 Therefore, it is difficult to define the CTV 
margin of radiotherapy for esophageal cancer without a 
clear understanding of the LNM pattern. CTVs include two 
components, the subclinical invasion and intramural metastasis 
of primary tumor, and the subclinical lymph node (CTVn). In 
Radiation Therapy Oncology Group 85–01,21 the irradiation 
field was extended from the supraclavicular region downward 
to the gastroesophageal junction, though the supraclavicular 
nodes were omitted in patients with tumors in the lower third 
TABLE 3.  Rate of LNM to Different Regions According to the Location of the Primary Tumor
Location Cervical Um Mm Lm Abdominal
Ut 12/82 (14.6) 24/82 (29.3) 7/82 (8.5) 8/82 (9.8) 6/82 (7.3)
Mt 55/1266 (4.3) 63/1266 (5.0) 417/1266 (32.9) 32/1266 (2.5) 189/1266 (14.9)
Lt 11/545 (2.0) 12/545 (2.2) 84/545 (15.4) 208/545 (38.1) 150/545 (27.5)
Total 78/1893 (4.1) 99/1893 (5.2) 508/1893 (26.8) 248/1893 (13.1) 345/1893 (18.2)
LNM, lymph node metastasis; Ut, upper thoracic; Mt, middle thoracic; Lt, lower thoracic; Um, upper mediastinal; Mm, middle mediastinal; Lm, lower mediastinal.
FIGURE 1.  Rate of LNM in different regions accord-
ing to the location of the primary tumor. LNM, lymph 
node metastasis.
TABLE 4.  Lymph Node Metastasis to Different Regions According to Location of Primary Tumor
No.
Upper Thoracic Middle Thoracic Lower Thoracic
Location Cases (%) Location Cases (%) Location Cases (%)
1 106R 23/82 (28.0) 108 353/1266 (27.9) 110 149/545 (27.3)
2 107 13/82 (15.9) 107 267/1266 (21.1) 108 138/545 (25.3)
3 105 12/82 (14.6) 7 175/1266 (13.8) 7 95/545 (17.4)
4 106TL 10/82 (12.2) 3 145/1266 (11.5) 107 90/545 (16.5)
5 108 8/82 (9.6) 110 118/1266 (9.3) 2 54/545 (9.9)
6 110 8/82 (9.6) 2 63/1266 (5.0) 3 48/545 (8.8)
7 106TR 7/82 (8.5) 109 60/1266 (4.7) 111 35/545 (6.4)
8 7 7/82 (8.5) 105 49/1266 (3.9) 8 26/545 (4.8)
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of the esophagus. In a subsequent study, Radiation Therapy 
Oncology Group 94–05,22 a 5-cm margin superior and inferior 
to and a 2-cm margin lateral to the block edge were used in a 
typical esophageal cancer protocol. This study mainly focused 
on the CTVn of ESCC patients. Obviously, CTVn is not to be 
considered in the CTV delineation. Locoregional recurrence 
because of missed targets and treatment-related toxicity, 
caused by large fields of radiation, still occur in a substantial 
proportion of patients. In summary, that may be the reason 
that locoregional control rates and the 5-year overall survival 
rate are low for advanced esophageal carcinoma patients after 
radiation therapy.
In our study, those sites with LNM rate higher than 15%, 
an empirical cutoff value, were considered as high-risk areas 
and were included in the target volume of patients with tho-
racic ESCC. Tumor invasion into the esophageal submucosa 
could cause regional LNM. Deeper tumor invasion can lead to 
more opportunities of tumor cells invading lymphatic vessels 
and higher rates of LNM.11,23 The results of subgroup analysis 
also suggest that radiation oncologists should design individu-
alized radiotherapeutic CTVn for thoracic ESCC patients with 
different tumor invasion. For T3–4 upper thoracic ESCC, we 
suggest that cervical and upper mediastinal nodes should be 
included in the CTV. The bidirectional transfer probability of 
middle thoracic esophageal carcinoma is higher. Therefore, 
more comprehensive coverage of mediastinal lymph nodes 
should be considered. CTV for T3–4 middle thoracic ESCC 
should include middle mediastinal and abdominal portions, 
whereas for T1–2 ESCC, only the middle mediastinal lymph 
nodes may be delineated as irradiation target volume. With 
regard to the T3–4 lower thoracic ESCC, the CTV should 
cover the middle, lower mediastinal, and abdominal regions, 
whereas for T1–2 ESCC, only the lower mediastinal and 
abdominal regions should be considered.
In addition, it is important for the radiation oncologist 
to recognize that tumor length is included in the classification 
of disease stage. It has been reported that length is associated 
with LNM rate, suggesting that longitudinal growth in the 
lymphatic-rich submucosa may be the most important factor 
resulting in regional LNM.24 The patients were divided into 
three groups by their tumor length (greatest dimension): 4 cm 
or lesser, 4 to 6 cm, and 6 cm or more. For middle thoracic 
ESCC patients with tumors measuring 4 to 6 cm or 6 cm and 
more, middle mediastinal and abdominal portions should be 
TABLE 5.  Multivariate Analysis of Risk Factors Associated with Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma
Parameters B S.E. Wald Sig. OR 95%CI for OR
Age −0.012 0.005 5.437 0.020 0.988 0.978–0.998
Path 0.044 0.065 0.456 0.500 1.045 0.920–1.188
Depth 0.561 0.068 68.929 <0.001 1.753 1.536–2.002
Length 0.144 0.027 28.131 <0.001 1.155 1.095–1.218
Diff 0.683 0.076 80.139 <0.001 1.980 1.705–2.299
Depth, the depth of tumor invasion; Length, the length of tumor; Diff, the histologic differentiation; Path, pathological morphology type; OR, odds ratios; CI, confidence interval.
TABLE 6.  Lymph Node Metastasis Rate Percentages in Tumor Invasion, Tumor Differentiation and Length of Tumor (%)
Location Cervical Um Mm Lm Abdominal
Depth of tumor invasion
T1–2 Mt 10/315 (3.2) 9/315 (2.9) 58/315 (18.4) 6/315 (1.9) 34/315 (10.8)
Lt 0/128 (0) 0/128 (0) 11/128 (8.6) 37/128 (28.9) 26/128 (20.3)
T3–4 Mt 45/951 (4.7) 54/951 (5.7) 359/951 (37.7) 26/951 (2.7) 155/951 (16.3)
Lt 11/417 (2.6) 12/417 (2.9) 73/417 (17.5) 171/417 (41.0) 124/417 (29.7)
Tumor differentiation
Higher Mt 44/1083 (4.1) 55/1083 (5.1) 338/1083 (31.2) 25/1083 (2.3) 142/1083 (13.1)
Lt 10/456 (2.2) 12/456 (2.6) 65/456 (14.3) 157/456 (34.4) 121/456 (26.3)
Lower Mt 11/183 (6.0) 8/183 (4.4) 79/183 (43.2) 7/183 (3.8) 47/183 (25.7)
Lt 1/89 (1.1) 0/890 (0) 19/89 (21.3) 51/89 (57.3) 29/89 (29.3)
Length of tumor
≤4 cm Mt 22/ 706 (3.1) 25/706 (3.5) 195/706 (27.6) 14/706 (2.0) 79/706 (11.2)
Lt 5/303 (1.7) 3/303 (1.0) 43/303 (14.2) 102/303 (33.7) 76/303 (25.1)
4–6 cm Mt 24/ 419 (5.7) 27/419 (6.4) 156/419 (37.2) 12/419 (2.9) 82/419 (19.6)
Lt 6/171 (3.5) 8/171 (4.7) 30/171 (17.5) 77/171 (45.0) 51/171 (29.8)
≥6 cm Mt 9/141 (6.4) 11/141 (7.8) 66/141 (46.8) 6/141 (4.3) 28/141 (19.9)
Lt 0/71 (0) 1/71 (1.4) 11/71 (15.5) 29/71 (40.8) 23/71 (32.4)
Mt, middle thoracic; Lt, lower thoracic; Um, upper mediastinal; Mm, middle mediastinal; Lm, lower mediastinal.
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included in the CTV. However, for patients with tumors mea-
suring 4 cm or lesser, only middle mediastinal should be delin-
eated as irradiation target volume. For lower thoracic ESCC 
patients with tumors measuring 4 to 6 cm or 6 cm and more, 
the CTV should cover the middle, lower mediastinal, and 
abdominal regions. Whereas for patients with tumors 4 cm or 
lesser, only lower mediastinal and abdominal regions should 
be delineated as irradiation target volume.
Incidence of LNM was significantly high in patients 
with poorly differentiated tumors than those with well- 
differentiated tumors.25 For middle thoracic ESCC patients 
with poorly differentiated tumors, the middle mediastinal and 
abdominal portions should be included in the CTV. However, 
for patients with well-differentiated tumors, only the middle 
mediastinal should be delineated as irradiation target volume. 
For lower thoracic ESCC patients with poorly differenti-
ated tumors, the CTV should cover the middle, lower medi-
astinal and abdominal regions. Whereas for patients with 
well- differentiated tumors, only the lower mediastinal and 
abdominal regions should be delineated as irradiation target 
volume. Because of the limit of the number of patients with 
upper thoracic ESCC, we cannot draw clear conclusions on 
different subgroups.
The results of further subgroup analysis suggest that 
T3–4 thoracic ESCC patients with tumors measuring 4 to 6 cm 
or 6 cm and more may still have a substantial risk for LNM, 
especially if histologic differentiation is poor. Therefore, for 
the large, deeply invasive, longer tumors, and poorly differen-
tiated thoracic ESCC, the irradiation field should be enlarged 
appropriately. Factors identified as independent prognostic 
factors for LNM in our analysis were depth of tumor invasion, 
length of tumor, and histologic differentiation. The incidence 
of LNM was significantly higher for thoracic ESCC patients 
with one or more of these independent risk factors. Therefore, 
we suggest that the irradiation field should be enlarged appro-
priately for these patients.
Nakagawa et al.26 reported that for each part of thoracic 
ESCC, the LNM rate of cervical and upper mediastinal lymph 
nodes is higher. The lower neck and upper mediastinum are 
rich in lymphatic vessels, nerves, and large blood vessels adja-
cent to organs. Therefore, it is difficult to perform a complete 
lymphadenectomy, leading to residual subclinical lesions, 
LNM, and recurrence of esophageal cancer.24 Thus, cervi-
cal and upper mediastinal lymph nodes theoretically need 
to be irradiated for all thoracic ESCC. Yet, our results show 
that LNM rate of cervical and upper mediastinal sites for the 
lower thoracic esophageal carcinoma were 2.0% and 2.2%, 
respectively. Although these two sites were once suggested in 
radiation therapy for lower thoracic esophageal carcinoma, we 
advocate them free of irradiation for the toxicity and compli-
cation of extensive radiotherapy. An irradiation field that is too 
small may miss the cancerous cells, whereas an overly large 
field will cause unnecessary radiation damage.
The risk is that larger CTVs carry a higher risk for nor-
mal tissue toxicity. How to minimize the damage to the radio-
sensitive organs close to the tumor is a major challenge for 
radiation oncologists, especially as concurrent chemoradio-
therapy is becoming a standard treatment. The choice of inten-
sity-modulated radiotherapy technique is clearly important. In 
the treatment of esophageal carcinoma, intensity-modulated 
radiotherapy may be used either to reduce the dose delivered 
to normal tissue, or to escalate the dose delivered to esopha-
geal tumors.27
In conclusion, CTV must be customized by experienced 
oncologists according to the various clinical factors that 
influence LNM. Irradiation of the selective regional lymph 
node and the correlated lymphatic drainage regions should 
be performed according to the clinical and pathological 
factors, such as depth of tumor invasion, length of tumor, and 
the histologic differentiation. For the large, deeply invasive 
longer tumors and poorly differentiated thoracic ESCC, the 
irradiation field should be enlarged appropriately.
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